Pazopanib Well-Tolerated in Young With Primary Multimetastatic Ewing Sarcoma

MONDAY, Oct. 27, 2025 (HealthDay News) -- For young patients with primary multimetastatic Ewing sarcoma, pazopanib is well-tolerated and effective, according to